Published: 29 September 2018
Author(s): Kristaps Sablinskis, Matiss Sablinskis, Aivars Lejnieks, Andris Skride
Section: Letter to the Editor

Pulmonary hypertension (PH) is a complex, progressing and debilitating pulmonary vascular disease associated with poor prognosis. Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are two distinct subtypes of PH with different pathophysiologic mechanisms and treatment strategies [1]⁠.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.